Loading...
Decitabine/Cedazuridine: First Approval
A fixed dose oral combination (FDC) of decitabine and cedazuridine (Inqovi(®)), is being developed by Astex Pharmaceuticals (a subsidiary of Otsuka Pharmaceuticals) for the treatment of various cancers like myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML), acute myeloid leuka...
Na minha lista:
| Udgivet i: | Drugs |
|---|---|
| Hovedforfatter: | |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Springer International Publishing
2021
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7708383/ https://ncbi.nlm.nih.gov/pubmed/32860582 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40265-020-01389-7 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|